Full-Time

Director – Global Value

Access & Pricing; Solid Tumors, Pipeline

Posted on 5/9/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$183.7k - $243.7k/yr

+ Annual bonus plan + Incentive compensation plan + Discretionary equity awards + Employee Stock Purchase Plan

Remote in USA

Remote

Category
Business & Strategy (2)
,
Requirements
  • BA/BS degree is required, MA/MS or higher preferred.
Responsibilities
  • Lead the creation and implementation of global pricing and market access strategies for Solid Tumor pipeline products (typically but not exclusively Phase II and III assets), aligning with clinical and commercial goals.
  • Collaborate cross-functionally to integrate access requirements into the development process, influencing trial design, endpoints, and evidence generation to meet payer needs.
  • Lead the collection and aggregation of feedback from all regions in which the Company operates and develop recommendations regarding clinical development and other evidence generation based on that feedback.
  • Represent the GVAP Solid Tumors perspective to governance or oversight bodies of the Company (e.g., GPT, GBT) in alignment with Regions and/or focus markets and Health Economics and Outcomes Research.
  • Develop early value propositions that resonate with global payers and support future pricing, reimbursement, and access decisions.
  • Work closely with Clinical, Medical Affairs, and Health Economics and Outcomes Research teams to shape clinical trial design and evidence-generation strategies that align with target market access requirements.
  • Identify and prioritize evidence gaps; work with Health Economics and Outcomes Research to ensure development of health economic models, burden-of-illness studies, and other data to address payer concerns and enhance product differentiation.
  • Serve as the primary market access point of contact for one or more governance and regional teams, if delegated by the Executive Director, GVAP ST.
  • Collaborate with Research and Development, Commercial, Medical Affairs, and Regulatory Affairs to ensure access-related insights are integrated into the overall development strategy.
  • Provide input into clinical decisions and Business Development to ensure payer requirements are recognized and addressed, or additional evidence generated, in support of the commercial strategy.
  • Engage with focus markets and regional access teams to align on access strategies and adapt for local market needs.
  • Align on early asset target product profile definitions and evidence required and planned value proposition to reduce pricing and reimbursement uncertainties across regions.
  • Drive pre-launch planning for pipeline products, including early value toolkits and relevant value in control analyses and early engagement strategies to optimize future access and reimbursement.
  • Support market access launch readiness through regular communication, training, and support to regional and affiliate teams as product nears market entry.
  • Support regional activities relating to regional asset in-licensing for early pipeline products.
  • Continuously monitor the solid tumor landscape, including competitor activities, payer requirements, and regulatory changes that impact access and reimbursement.
  • Analyze payer insights, pricing trends, and market conditions to inform strategy adjustments and refine access plans.
  • Use global and regional insights to refine value propositions and enhance product positioning as the product advances through clinical phases.
  • Lead early pipeline consultation processes with payers across regions (e.g., CADTH, NICE).
  • No direct supervision, high level of cross-functional and pan-regional collaborations with internal stakeholders.
Desired Qualifications
  • Experience from pipeline/early development and JCA preparation is a strong advantage.
  • Knowledge of health technology assessment methods and health economics modeling is an advantage.
  • Fluency in English is required; a second language is an advantage.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • BRUKINSA sales reached $3.9B in 2025, growing 49% year-over-year.
  • TEVIMBRA plus ZIIHERA shows extended survival versus trastuzumab in gastric cancer.
  • Three solid tumor programs advancing to late-stage trials with 60+ abstracts.

What critics are saying

  • BRUKINSA represents 73% of revenue; market share loss to competitors accelerates decline.
  • BEQALZI conditional approval requires CELESTIAL-RRMCL Phase 3 trial success by 2027.
  • Generic ibrutinib competition by 2027-2028 forces BRUKINSA price cuts or market share loss.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL.
  • BEQALZI is first BCL2 inhibitor approved for relapsed/refractory mantle cell lymphoma.
  • Global GMP manufacturing network enables cost-efficient drug development across 45+ countries.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BeOne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...